Personalisation of dexamethasone in childhood acute lymphoblastic leukaemia
Dexamethasone (dex) is a key treatment for childhood acute lymphoblastic leukaemia (ALL), but is associated with significant variability in terms of toxicity and efficacy. In this project, the following variables were assessed to better understand how dex personalisation may be achieved: pharmacokin...
| Main Author: | |
|---|---|
| Published: |
University of Newcastle upon Tyne
2017
|
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.757083 |